| Identification | Back Directory | [Name]
CXL-1020 | [CAS]
950834-06-7 | [Synonyms]
CXL-1020
N-hydroxy-2-methylsulfonylbenzenesulfonamide
Benzenesulfonamide, N-hydroxy-2-(methylsulfonyl)- | [Molecular Formula]
C7H9NO5S2 | [MOL File]
950834-06-7.mol | [Molecular Weight]
251.28 |
| Hazard Information | Back Directory | [Uses]
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure[1]. | [in vivo]
CXL-1020 (100 μg/kg/min; infusion for 30 min) improves hemodynamics and cardiac function, and enhances both diastolic and systolic performance in mice[1].
CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure[2]. | Animal Model: | Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction by isoproterenol)[1] | | Dosage: | 100 μg/kg/min | | Administration: | For 30 min | | Result: | Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice. |
| Animal Model: | Dogs (coronary microembolization-induced heart failure)[2]
3 and 10 mg/kg/min | | Dosage: | 3 and 10 mg/kg/min | | Administration: | 4-hour intravenous infusion | | Result: | Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner. |
| [IC 50]
L-type calcium channel | [References]
[1] Roof SR, et al. CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat. Front Physiol. 2017 Nov 10;8:894. DOI:10.3389/fphys.2017.00894
[2] Mengjun Wang, et al. Intravenous Infusion of CXL-1020, a Novel Nitroxyl (HNO) Donor, Improves Left Ventricular Systolic and Diastolic Function in Dogs with Advanced Heart Failure. CARDIOVASCULAR PHARMACOLOGY. VOLUME 15, ISSUE 6, SUPPLEMENT, S73-S74, AUGUS |
|
|